Pharmaceuticals

Increasing Prevalence Of Osteogenesis Imperfecta Fueling The Growth Of The Market Due To Improved Diagnosis And Patient Registries Is Supporting Development Across The Osteogenesis Imperfecta Treatment Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Osteogenesis Imperfecta Treatment Market By 2030 Based On Its 2026 Value?

The osteogenesis imperfecta treatment market has experienced consistent expansion in recent times. This market is projected to expand from $0.93 billion in 2025 to reach $0.98 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this historical growth include the scarcity of available treatment methods for osteogenesis imperfecta, a dependence on traditional bisphosphonate therapies, insufficient patient understanding of lifestyle management, constrained access to specialized surgical procedures, and an underdeveloped infrastructure for homecare support.

The osteogenesis imperfecta treatment market size is anticipated to show steady expansion in the coming years. It is predicted to reach $1.16 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 4.3%. The forecasted growth can be attributed to the development of novel drugs and hormone therapies, progress in minimally invasive rodding and spinal surgeries, the integration of telemedicine in homecare, an increasing focus on patient-centric lifestyle and rehabilitation programs, and the rising adoption of precision medicine approaches. Significant trends during the forecast period include the increased uptake of bisphosphonate and teriparatide therapies, growth in rodding and spinal fusion surgeries, an escalating demand for personalized physical therapy programs, the expansion of homecare and specialty clinic services, and an enhanced focus on patient education and lifestyle management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24639&type=smp

What Are The Main Drivers Accelerating The Growth Of The Osteogenesis Imperfecta Treatment Market?

The growing occurrence of osteogenesis imperfecta (OI) is projected to fuel the expansion of the osteogenesis imperfecta treatment market in the future. This genetic condition, known as osteogenesis imperfecta, is identified by easily fractured, delicate bones and impacts people of all ages. The uptick in OI prevalence stems from developments in genetic screening and the creation of both national and regional disease databases, which are uncovering cases that were previously undiagnosed. Treatment for osteogenesis imperfecta assists patients by offering therapies like bisphosphonates, intramedullary rods, braces, and other supportive services designed to enhance bone durability and overall quality of life. As an illustration, in July 2025, data from the Oxford Academic, a UK-based academic research platform, revealed that out of 5,722 persons having at least two medical claims related to osteogenesis imperfecta (OI) separated by a minimum of 30 days, 2,095 satisfied the CE eligibility requirements, forming the complete OI cohort. Consequently, the rising prevalence of OI is a key factor propelling the expansion of the osteogenesis imperfecta treatment market.

Which Segment-Based Categories Are Covered In The Osteogenesis Imperfecta Treatment Market?

The osteogenesis imperfecta treatment market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Physical Therapy, Lifestyle Modifications

2) By Drug Class: Teriparatide, Denosumab, Other Drug Classes

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Bisphosphonates, Teriparatide, Hormone Replacement Therapy, Pain Relievers, Calcium And Vitamin D Supplements

2) By Surgery: Rodding Surgery, Spinal Fusion Surgery, Fracture Repair Surgery, Joint Replacement Surgery

3) By Physical Therapy: Strength Training, Range Of Motion Exercises, Aquatic Therapy, Gait Training, Assistive Device Training

4) By Lifestyle Modifications: Nutritional Counseling, Fall Prevention Strategies, Home Environment Modification, Activity Modification, Patient Education And Support Programs

Which Trends Are Supporting The Evolution Of The Osteogenesis Imperfecta Treatment Market?

Companies operating within the osteogenesis imperfecta treatment market are concentrating on advanced therapeutics like sclerostin inhibition therapy to accelerate bone formation and diminish fracture risk in individuals suffering from osteogenesis imperfecta (OI). Sclerostin inhibition therapy functions by employing monoclonal antibodies to block sclerostin, a protein that restricts bone development, consequently promoting increased bone mineral density and resilience. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, was granted Breakthrough Therapy Designation by the FDA for its investigational therapy, setrusumab (UX143). Setrusumab is a fully human monoclonal antibody engineered to inhibit sclerostin, which in turn stimulates new bone formation and improves bone strength, aiming to reduce fracture risk in patients with OI Types I, III, and IV aged two years and older.

Which Industry Players Are Present In The Osteogenesis Imperfecta Treatment Market?

Major companies operating in the osteogenesis imperfecta treatment market are Amgen Inc., Ascendis Pharma A/S, Mereo BioPharma Group PLC, OrthoPediatrics Corp., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Kyowa Kirin Co. Ltd., Ipsen S.A., Alexion Pharmaceuticals (AstraZeneca Rare Disease), Takeda Pharmaceutical Company Limited, Novartis AG (Bone Metabolism Portfolio), Roche Holding AG (Genentech), Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Stada Arzneimittel AG, Fresenius Kabi AG, Alkem Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., Accord Healthcare Ltd., Sandoz Group AG, Medtronic plc, Smith & Nephew plc, Zimmer Biomet Holdings Inc.

Access The Complete Osteogenesis Imperfecta Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/osteogenesis-imperfecta-treatment-global-market-report

Which Region Has The Strongest Presence In The Osteogenesis Imperfecta Treatment Market?

North America was the largest region in the osteogenesis imperfecta treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteogenesis imperfecta treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Osteogenesis Imperfecta Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24639&type=smp

Browse Through More Reports Similar to the Global Osteogenesis Imperfecta Treatment Market 2026, By The Business Research Company

Osteoporosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report

Mineral And Bone Disorder Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

Orthopedic Soft Tissue Repair Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-soft-tissue-repair-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795